United States: Licensing & Syndication

Subscribe
Intellectual property law and copyright law thought leadership, articles, podcasts, videos and webinars from expert sources across the legal world. Explore insights covering topics such as licensing and syndication, patent law, trade secrets and trademark law.
Article
Cipla And Qilu Announce Exclusive U.S. Licensing And Supply Agreement For Pembrolizumab Biosimilar
InvaGen Pharmaceuticals Inc., a Cipla Limited subsidiary, has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the licensing and supply of QL2107, a biosimilar to Merck's KEYTRUDA® (pembrolizumab), in the United States. This collaboration represents the latest in a series of partnering transactions directed to pembrolizumab biosimilar candidates, with Qilu handling development and regulatory registration while Cipla USA manages commercialization.
United States Healthcare
GP
Goodwin Procter LLP
Article
Paul Bain's Book, Art Law: Cases And Controversies, 2nd Edition, Was Published By LexisNexis
Paul Bain has completed the second edition of Art Law: Cases and Controversies, a comprehensive legal guide published by LexisNexis that examines the intricate legal frameworks governing art creation, transactions, collecting, and preservation. The publication features contributions from leading professionals and addresses how traditional art law principles intersect with modern challenges posed by the Internet and artificial intelligence technologies.
United States IP
DW
Dickinson Wright PLLC
Article
Is This Real? Navigating AI Impersonation Under New And Existing Laws
Is this AI-generated, or is it real? As generative AI tools have become increasingly capable of creating realistic images, videos, and audio, they have also made it easier to impersonate real people without their consent. In response, states are increasingly adopting laws that impose civil and criminal liability for certain AI-generated content that replicates an individual’s identity, likeness, voice, or other personal attributes.
United States IP
WR
Wiley Rein
Article
European Patent Office Updates Its Guidelines For Examination
The European Patent Office has released its April 2026 Guidelines for Examination, introducing significant changes to procedural and substantive patent law. Key updates include modifications to the PACE acceleration program, new claim interpretation standards following the G1/24 decision, relaxed novelty requirements for products placed on the market under G1/23, and refined guidance on further medical use claims under Article 54(5) EPC.
Worldwide IP
OM
Oblon, McClelland, Maier & Neustadt, L.L.P
Article
USPTO Reinstates Double Patenting Rejections In Ex Parte Baurin: What Life Sciences Innovators Need To Know
The USPTO Appeals Review Panel's August 2026 decision in Ex parte Baurin reinstated nonstatutory double patenting rejections against Sanofi's antibody-like binding protein application, even though the application would expire before the reference patent. This precedential ruling raises critical questions about whether the risk of harassment by multiple patent owners alone justifies double patenting rejections, particularly when no extension of patent term exists.
United States IP
FH
Foley Hoag LLP
Article
Teva And Polpharma Biologics Announce Global Licensing Agreement For Ocrelizumab Biosimilar For Multiple Sclerosis
Teva Pharmaceuticals and Polpharma Biologics have entered into a global licensing agreement for the commercialization of a biosimilar candidate to Genentech's OCREVUS (ocrelizumab), a treatment for multiple sclerosis. The agreement combines Polpharma Biologics' development expertise with Teva's commercial capabilities across major markets including the United States, Europe, and several other territories. Under the terms, Polpharma Biologics will handle development and manufacturing while Teva manages regul
United States Healthcare
GP
Goodwin Procter LLP
Article
Non-U.S. Trademark Registrants Beware!
When a non-U.S. company obtains a U.S. trademark registration based on a foreign registration without U.S. use, failing to file the required Declaration of Use within six years can result in cancellation with serious consequences. A recent TTAB decision demonstrates how a lapsed registration loses all protective value, even against later-filed confusingly similar marks that were registered while the original registration was still active.
United States IP
CL
Cowan Liebowitz & Latman PC
Article
A New Framework For AI Permissions In Entertainment: RSL Media’s Human Consent Standard
RSL Media has introduced the Human Consent Standard, a machine-readable protocol allowing individuals to declare whether AI systems may use their creative works, identity, likeness, voice, characters, or marks. While endorsed by major entertainment industry figures and organizations, the voluntary standard's effectiveness depends on pending federal legislation like the NO FAKES Act, voluntary adoption by AI developers, and its ability to withstand contractual pressures that could undermine its protective fu
United States IP
GA
Global Advertising Lawyers Alliance (GALA)
Article
Intelligence Piracy: The Actor Who Was Never There
Artificial intelligence has created a new form of piracy in film and television, one that doesn't steal finished works but instead extracts the craft and identity of performers themselves. From synthetic actors like Tilly Norwood to unauthorized digital replicas of real stars, the industry faces a fundamental question: when AI learns to recreate a performer's face, voice, and mannerisms from their body of work, whose craft has been taken?
United States IP
R
Rouse
Article
Term Sheet, Real Deal: Delaware Court Signals Willingness To Specifically Enforce Technology License
The Delaware Court of Chancery examines whether a November 2023 term sheet constitutes a binding licensing agreement for emotion-recognition AI technology, and whether specific performance can compel transfer of intellectual property rights. Vice Chancellor Zurn signals inclination to enforce the agreement and grant the extraordinary remedy, raising critical questions about contracting for undeveloped AI technology and the enforceability of automatic IP transfer provisions.
United States IP
HL
Hogan Lovells Cadwalader
See more

Latest Videos

See more